Skip to content

Non-Hodgkin's lymphoma risk increased with prolonged high HIV viral load

Two integrase inhibitors now making progress in clinical trials

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

Study finds antiretroviral therapy cost-effective in South African setting

Clinical and immunological benefits lasting at least three years reported by large Kenyan antiretroviral programme

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

ICAAC: Women who shed HSV in genitals shed more HIV

ICAAC: HCV only factor associated with liver problems in patients starting HIV treatment in 2004

ICAAC: Dividing Triomune tablets may result in inadequate doses for small children; liquid best